GH Research (GHRS) said Friday that it submitted a complete response to the US Food and Drug Administration for an investigational new drug application for GH001, its lead product candidate which is being developed as a medication for individuals with treatment-resistant depression.
The regulator previously placed the application on clinical hold, according to the company.
Shares of the biopharmaceutical company were up 2.1% in recent trading.
Price: 12.09, Change: +0.25, Percent Change: +2.07
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。